Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
Authors
Keywords
-
Journal
JAMA Oncology
Volume 7, Issue 12, Pages 1873
Publisher
American Medical Association (AMA)
Online
2021-10-19
DOI
10.1001/jamaoncol.2021.3595
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
- (2021) Aanika Balaji et al. Journal for ImmunoTherapy of Cancer
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
- (2021) A. Spira et al. Journal of Thoracic Oncology
- Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?
- (2020) Elhai M et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- FDA Approval Summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer
- (2020) Suparna Wedam et al. CLINICAL CANCER RESEARCH
- HER2-Low Breast Cancer: Pathological and Clinical Landscape
- (2020) Paolo Tarantino et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
- (2020) Salvatore Siena et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
- (2020) Michelle D. Hackshaw et al. BREAST CANCER RESEARCH AND TREATMENT
- 1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
- (2020) K. Yamaguchi et al. ANNALS OF ONCOLOGY
- 289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies
- (2020) C.A. Powell et al. ANNALS OF ONCOLOGY
- Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
- (2020) Leisha A Emens et al. LANCET ONCOLOGY
- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-Induced Interstitial Lung Disease: A Systematic Review
- (2018) Sarah Skeoch et al. Journal of Clinical Medicine
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- (2017) Myriam Delaunay et al. EUROPEAN RESPIRATORY JOURNAL
- Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF)
- (2017) Adelle Jee et al. Journal of Clinical Medicine
- Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
- (2016) Rashmi R. Shah DRUG SAFETY
- mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm
- (2015) Annelieke E.C.A.B. Willemsen et al. INTERNATIONAL JOURNAL OF CANCER
- FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports
- (2011) Noritoshi Yoshii et al. ANTI-CANCER DRUGS
- Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer
- (2011) Kanako Inaba et al. MEDICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started